Breakthrough Therapy Designation Status, Top-Line Results, and Business Proposals Boost Long-Term Growth in Pharmaceutical Companies - Research Report on Novartis, AstraZeneca, GSK, Sanofi, and Rigel

Wed Jun 26, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Breakthrough Therapy Designation Status, Top-Line Results, and Business Proposals Boost Long-Term Growth in Pharmaceutical Companies - Research Report on Novartis, AstraZeneca, GSK, Sanofi, and Rigel

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Novartis AG (NYSE: NVS), AstraZeneca PLC (NYSE: AZN), GlaxoSmithKline plc (NYSE: GSK), Sanofi (NYSE: SNY), and Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Novartis AG Research Report

On June 21, 2013, Novartis AG (Novartis) announced that the US Food and Drug Administration (FDA) has granted its RLX030 (serelaxin) a Breakthrough Therapy Designation status. RLX030 (serelaxin) is an investigational treatment for patients with acute heart failure (AHF). Novartis reported that the US FDA's decision was supported by the efficacy and safety results from the Phase III RELAX-AHF trial, which also showed that patients who received RLX030 had a 37% reduction in mortality at 6 months after an acute heart failure episode compared to those who received conventional treatment. David Epstein, Division Head of Novartis Pharmaceuticals, stated, "RLX030 is representative of Novartis' strong commitment to develop innovative treatments for patients in areas of significant unmet need." Epstein added, "Commonly used medicines for AHF only improve the immediate symptoms, so the additional effect on survival observed with RLX030 offers hope to patients and physicians." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/956c_NVS ]

--

AstraZeneca PLC Research Report

On June 19, 2013, AstraZeneca PLC (AstraZeneca) and Bristol-Myers Squibb announced the top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza (saxagliptin). AstraZeneca reported that Onglyza met the primary safety objective of non-inferiority and did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo. The Company stated that the preliminary data of SAVOR-TIMI-53 are being analyzed, and the study results will be submitted to the European Society of Cardiology (ESC) for potential presentation at the ESC Congress in September 2013. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/02c7_AZN ]

--

GlaxoSmithKline plc Research Report

On June 18, 2013, GlaxoSmithKline plc (GSK) announced that it has received an offer from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited for its thrombosis brands and Notre-Dame de Bondeville (NBD) site. GSK reported that it has agreed on a period of exclusivity with Aspen, and the Company will respond to the offer subject to consultation with employees and the relevant work councils. The financial terms of the proposal were kept confidential, but the offer includes the transfer of Arixtra and Fraxiparine brands (excluding China, India, and Pakistan) to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees. GSK stated that the Aspen proposal is aligned with its strategy of focusing on products with the most growth potential and on the delivery of its pipeline. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/2737_GSK ]

--

Sanofi Research Report

On June 22, 2013, Sanofi announced the first Phase III study results (EDITION I) of its investigational new insulin U300, which showed equivalent blood sugar control with fewer night-time low blood sugar events, compared with Lantus (insulin glargine [rDNA origin] injection). Sanofi also announced top-line results for its second Phase III study (EDITION II) of new insulin U300, which showed similar blood sugar reduction while fewer patients experienced night-time low blood sugar events, compared with Lantus. Matthew Riddle, Professor of Medicine, Division of Endocrinology/Diabetes/Clinical Nutrition, Oregon Health and Science University, U.S., and Principal Investigator for the EDITION I study, commented, "To properly manage diabetes, it is critical to control blood sugar and to reduce the risk of low blood sugar events, especially at night." Riddle continued, "I am encouraged by these findings, and look forward

to the results of the full Phase 3 EDITION program, which will further reveal how this investigational

basal insulin may help people living with diabetes." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/26eb_SNY ]

--

Rigel Pharmaceuticals, Inc. Research Report

On June 4, 2014, Rigel Pharmaceuticals, Inc. (Rigel) and AstraZeneca AB (AZ) announced top-line results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). James M. Gower, Chairman and CEO of Rigel, said, "Fostamatinib continues to demonstrate positive patient outcomes and a reasonable safety profile." Gower continued, "We are looking forward to receiving and evaluating the full aggregation of AZ's efforts on this program this summer as we consider the appropriate next steps with this product candidate." The Full Research Report on Rigel Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/c2b9_RIGL ]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.